14 studies on Kpv curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 1,988 published Kpv COA source records from third-party laboratories, covering 719 publicly attributable vendor identities. Across 1,755 records with positive numeric purity, the arithmetic mean is 99.56%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 1 positive purity results are below 90%; 75 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.00 | $6.00–$6.00 | $1.20 | 1 source · 1 offer |
| 10 mg | $9.38 | $8.50–$10.50 | $0.94 | 4 sources · 4 offers |
| 30 mg | $26.00 | $26.00–$26.00 | $0.87 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-18T19:57:04.956696+00:00. Calculation time is not a laboratory observation date.
Within that total, 683 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 36 | 99.5% | 0 of 28 (0.0%) 0 0% / not detected · 0 wrong compound · 8 unclassified | Reveal with Pro → | |
| #2 | 25 | 99.63% | 0 of 20 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #3 | 17 | 99.31% | 0 of 15 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120496 (99.16%) · #120409 (99.23%) · #120408 (99.82%) · #120381 (99.56%) · #120493 (99.97%) · #120327 (99.85%)
**Alpha-MSH and KPV may offer a dual-action profile** — simultaneously controlling excessive inflammation while actively killing pathogens — that no conventional anti-inflammatory drug achieves. Standard NSAIDs and co…
**KPV's ability to suppress `NF-κB`-driven HIV transcription in primary macrophages** positions it as a mechanistically grounded candidate for adjunctive anti-HIV strategies targeting the macrophage reservoir — a comp…
**alpha-MSH and KPV represent a dual-action immunotherapeutic strategy**: simultaneously suppressing pro-inflammatory cytokine cascades and actively inducing antigen-specific tolerance via CTLA4(+)/IL-10(+) T cells — …
**The assumed requirement for cyclic AMP in KPV and alpha-MSH anti-inflammatory action must be reconsidered** — at least in keratinocytes, the operative second messenger appears to be intracellular calcium, not cAMP. …
This research identifies [Ac-CKPV]2 as a highly promising candidate for the development of new therapies for fungal infections, particularly those caused by drug-resistant Candida strains which are difficult to treat.…
**KPV and K(D)PT represent a structurally minimal, pharmacologically potent anti-inflammatory scaffold** that could be developed into topical, ophthalmic, or oral formulations for inflammatory skin, eye, and bowel dis…
**KPV's activity at nanomolar concentrations via an endogenous transporter (`PepT1`) that is upregulated specifically during intestinal inflammation creates a self-amplifying targeting mechanism** — diseased tissue co…
**KPV's efficacy in two mechanistically distinct colitis models, including survival rescue in MC1R-null animals, meaningfully broadens its therapeutic relevance** beyond a single signaling pathway — a common liability…
**KPV and KdPT reframe the anti-inflammatory potential of α-MSH by stripping it down to a receptor-independent, pigmentation-free tripeptide** — a meaningful leap for any clinician or researcher frustrated by full-hor…
This study reveals a dual role for the `PepT1` transporter: it's a promoter of colitis-associated cancer but also the necessary gateway for the anti-cancer effects of the peptide **KPV**. For individuals with IBD, ele…
This study presents a sophisticated oral delivery strategy that could significantly improve the treatment of ulcerative colitis with peptides like KPV. For individuals using peptides for inflammatory bowel conditions,…
This research introduces a promising new method for modifying peptides to enhance their stability, which could significantly extend their half-life in the body and reduce the required dosing frequency for therapeutic …
Free, no account — handy when you're working with Kpv.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account